Francescomassimo Lasorsa
Has grant
Full professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Finding new targets to counteract brain progenitor cells dysregulation in AGC1 deficiency hypomyelination: a multidisciplinary approach.
Open Date: 2019-11-01
Close Date: 2024-01-01
Grant: Close
Progetto Bandiera InterOmics “Omics investigations of AGC1 deficiency pathogenesis in iPS cells” – OMIxAGC1D
Open Date: 2017-01-01
Close Date:
Grant: Close
Role of mitochondrial uncoupling protein-2 in pancreatic ductal adenocarcinoma tumorigenesis and maintenance
Open Date: 2015-06-01
Close Date: 2018-05-01
Grant: Close
Molecular and cellular underpinnings of the neurological phenotypes associated to mitochondrial citrate carrier (SLC25A1) deficiency
Open Date: 2015-03-01
Close Date: 2016-02-01
Grant: Close
Metabolic flux analysis in cells derived from patients with mitochondrial carrier deficiency
Open Date: 2015-01-01
Close Date: 2015-12-01
Articles (8)
Year:
2026
Year:
2026
Year:
2026
AGC1 deficiency is a rare, early-onset encephalopathy caused by mutations in the SLC25A12 gene, encoding the mitochondrial aspartate/glutamate carrier isoform 1 (AGC1). Patients exhibit epileptic encephalopathy, cerebral hypomyelination, severe hypotonia, and global developmental delay. A hallmark biochemical feature of AGC1 deficiency is reduced brain N-acetylaspartate (NAA), a key metabolite involved in myelin lipid synthesis. However, the underlying mechanisms leading to the hypomyelinating phenotype remain unclear. In this study, we generated neuronal progenitors (NPs) derived from human-induced pluripotent stem cells (hiPSCs) of AGC1-deficient patients to investigate the metabolic and bioenergetic consequences of AGC1 loss. We demonstrated that AGC1-deficient NPs exhibit impaired proliferation, increased apoptosis, and a metabolic shift toward a hyperglycolytic phenotype due to defective mitochondrial pyruvate oxidation. RNA sequencing revealed downregulation of mitochondrial pyruvate carrier MPC1/2, limiting pyruvate-driven oxidative phosphorylation (OXPHOS) and reinforcing glycolysis as the primary energy source. Despite this metabolic shift, AGC1-deficient mitochondria retained the potential for OXPHOS when alternative anaplerotic substrates were provided. Notably, the administration of ketone bodies, in combination with glutamine, fully restored mitochondrial respiration, suggesting a mechanistic basis for the clinical improvements observed in AGC1-deficient patients undergoing ketogenic diet therapy. Our study highlights the importance of alternative metabolic pathways in maintaining neuronal energy homeostasis in AGC1 deficiency and offers insights into potential therapeutic strategies aimed at bypassing the mitochondrial pyruvate oxidation defect.
Year:
2025
Year:
2024
Aspartate–glutamate carrier isoform 1 (AGC1) is a carrier responsible for the export of mitochondrial aspartate in exchange for cytosolic glutamate and is part of the malate–aspartate shuttle, essential for the balance of reducing equivalents in the cells. In the brain, mutations in SLC25A12 gene, encoding for AGC1, cause an ultra-rare genetic disease, reported as a neurodevelopmental encephalopathy, whose symptoms include global hypomyelination, arrested psychomotor development, hypotonia and seizures. Among the biological components most affected by AGC1 deficiency are oligodendrocytes, glial cells responsible for myelination processes, and their precursors [oligodendrocyte progenitor cells (OPCs)]. The AGC1 silencing in an in vitro model of OPCs was documented to cause defects of proliferation and differentiation, mediated by alterations of histone acetylation/deacetylation. Disrupting AGC1 activity could possibly reduce the availability of acetyl groups, leading to perturbation of many biological pathways, such as histone modifications and fatty acids formation for myelin production. Here, we explore the transcriptome of mouse OPCs partially silenced for AGC1, reporting results of canonical analyses (differential expression) and pathway enrichment analyses, which highlight a disruption in fatty acids synthesis from both a regulatory and enzymatic stand. We further investigate the cellular effects of AGC1 deficiency through the identification of most affected transcriptional networks and altered alternative splicing. Transcriptional data were integrated with differential metabolite abundance analysis, showing downregulation of several amino acids, including glutamine and aspartate. Taken together, our results provide a molecular foundation for the effects of AGC1 deficiency in OPCs, highlighting the molecular mechanisms affected and providing a list of actionable targets to mitigate the effects of this pathology.
Year:
2024
Year:
2023
Year:
2023
Collaborators (15)
Salvatore Scacco
Professore Associato BIO/12
Loma Linda University
Michele Protti
Associate Professor
ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
Maria Eleonora Bizzoca
University of Foggia
Federico Giorgi
Associate Professor
University of Bologna
Andrea Ballini
Associate Professor
Link Campus University
Barbara Monti
Prof.ssa
University of Bologna
Takahisa Nakamura
Associate Professor
Cincinnati Children's Hospital Medical Center
Lorenzo Lo Muzio
Professore Ordinario
Università degli Studi di Foggia
Angelo Vozza
Professor of Biochemistry
University of Bari
Giuseppe Fiermonte
Full Professor
University of Bari Aldo Moro
Stefania Cantore
Associate professor
Link Campus University
Luigi Palmieri
-
Yookyung Jung
Research Assistant Professor
Albert Einstein College of Medicine
Giacomo Volpe
Associate Professor of Applied Biology
University of Bari Aldo Moro
Mariarosaria Boccellino
University of Campania “Luigi Vanvitelli”
Make your next move.
Prepare your application
Review drafts before you send them.